Kyowa Hakko Kirin Co. Ltd., of Tokyo, and Bristol-Myers Squibb Co., of New York, said they entered a clinical trial collaboration agreement to conduct a phase I/II combination study with mogamulizumab, an anti-CCR4 antibody, and Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor.